Development of Keap1 gene therapy for chemo-resistance endometrial cancer.

2014 Fiscal Year Final Research Report

• Project/Area Number: 24592500
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: Tohoku University
• Principal Investigator: YOSHINAGA Kousuke 東北大学, 医学(系)研究科(研究院), 非常勤講師 (40343058)
• Co-Investigator(Kenkyū-buntansha): NAGASE Satoru 山形大学, 医学部, 教授 (00292326) ; TAKANO Tadao 東北大学, 病院, 特任教授 (40282058)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 子宮内膜癌 / 化学療法抵抗性 / Keap1遺伝子 / Nrf2遺伝子 / 遺伝子治療

Outline of Final Research Achievements

Mutation of Keap1 and Nrf2 genes has been implicated in chemo- and radiation-resistance in multiple types of cancer. In this study, we uncovered involvement of the gene mutation in chemo-resistance endometrial cancer and established the human Keap1 expression vector. Moreover, microRNA-34b was also revealed to play a key role in proliferation, invasion and progression of cancer. Those results would promote to develop the Keap1 genetherapy for chemo-resistance endometrial cancer.

Free Research Field

産婦人科学